• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小儿非霍奇金淋巴瘤:临床及生物学预后因素与风险分层

Pediatric non-Hodgkin's lymphoma: clinical and biologic prognostic factors and risk allocation.

作者信息

Weitzman Sheila, Suryanarayan Kaveri, Weinstein Howard J

机构信息

Division of Hematology/Oncology, The Hospital For Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada.

出版信息

Curr Oncol Rep. 2002 Mar;4(2):107-13. doi: 10.1007/s11912-002-0071-6.

DOI:10.1007/s11912-002-0071-6
PMID:11822982
Abstract

The use of effective combination chemotherapy for all stages and subtypes of non-Hodgkin"s lymphoma (NHL) in children has resulted in a striking improvement in cure rates. Event-free survival now ranges from 70% to 90%, depending on the stage of disease and the NHL subtype. Risk-adapted therapy has resulted in a dramatic improvement in outcome for high-risk patients, at the cost of significantly increased short-term toxicity, and a reduction of therapy and toxicity for the lower-risk patient, while maintaining the excellent cure rate. Successful risk allocation of patients is dependent on the identification and continual validation of prognostic factors. The specific treatment protocol is the single most important factor predicting outcome today. Traditional prognostic factors such as stage and tumor burden are useful in selecting the intensity and length of therapy, rather than as a major indicator of likelihood of survival. In order to further improve cure rates and decrease toxicity, new biologic prognosticators need to be found and validated. Some promising avenues for study appear to be the presence or absence of adhesion molecules and of aberrant proteins that are specific to subtypes of lymphomas, such as soluble CD30 and anaplastic lymphoma kinase (ALK), the molecular classification of lymphomas on the basis of gene expression, and the evaluation of biologic markers for measuring early response to therapy.

摘要

对儿童非霍奇金淋巴瘤(NHL)的所有分期和亚型采用有效的联合化疗,已使治愈率显著提高。无事件生存率目前在70%至90%之间,具体取决于疾病分期和NHL亚型。风险适应性治疗已使高危患者的治疗结果有了显著改善,但代价是短期毒性显著增加,同时降低了低危患者的治疗强度和毒性,且保持了极高的治愈率。成功地对患者进行风险分类取决于对预后因素的识别和持续验证。具体的治疗方案是当今预测治疗结果的最重要单一因素。传统的预后因素,如分期和肿瘤负荷,在选择治疗强度和疗程方面有用,但并非生存可能性的主要指标。为了进一步提高治愈率并降低毒性,需要找到并验证新的生物学预后指标。一些有前景的研究途径似乎包括淋巴瘤亚型特异性的黏附分子和异常蛋白的有无,如可溶性CD30和间变性淋巴瘤激酶(ALK),基于基因表达的淋巴瘤分子分类,以及用于评估治疗早期反应的生物学标志物。

相似文献

1
Pediatric non-Hodgkin's lymphoma: clinical and biologic prognostic factors and risk allocation.小儿非霍奇金淋巴瘤:临床及生物学预后因素与风险分层
Curr Oncol Rep. 2002 Mar;4(2):107-13. doi: 10.1007/s11912-002-0071-6.
2
Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.奥地利儿童及青少年恶性非霍奇金淋巴瘤——1986年至2000年的治疗结果
Wien Klin Wochenschr. 2002 Dec 30;114(23-24):978-86.
3
Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.儿童和青少年非霍奇金淋巴瘤中枢神经系统受累的患病率、临床模式及转归因非霍奇金淋巴瘤亚型而异:柏林-法兰克福-明斯特集团报告
J Clin Oncol. 2007 Sep 1;25(25):3915-22. doi: 10.1200/JCO.2007.11.0700.
4
Non-Hodgkin's lymphoma. Biologic classification and implication for therapy.非霍奇金淋巴瘤。生物学分类及其对治疗的意义。
Pediatr Clin North Am. 1991 Apr;38(2):443-56. doi: 10.1016/s0031-3955(16)38086-5.
5
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.儿童和青少年非霍奇金淋巴瘤:根据生物学亚型和分期分层治疗的结果——柏林-法兰克福-明斯特集团报告
J Clin Oncol. 1995 Feb;13(2):359-72. doi: 10.1200/JCO.1995.13.2.359.
6
Non-Hodgkin's lymphoma.非霍奇金淋巴瘤
Curr Probl Cancer. 1996 Jan-Feb;20(1):6-77. doi: 10.1016/s0147-0272(96)80303-5.
7
[A collaborative study of children with lymphoblastic non-Hodgkin's lymphoma in China].[中国儿童淋巴细胞性非霍奇金淋巴瘤的一项合作研究]
Zhonghua Er Ke Za Zhi. 2015 Dec;53(12):931-7.
8
Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded).儿科肿瘤学组对107例非霍奇金淋巴瘤(不包括伯基特淋巴瘤)患儿采用改良LSA2-L2疗法的经验。
Cancer. 1985 Jan 15;55(2):323-36. doi: 10.1002/1097-0142(19850115)55:2<323::aid-cncr2820550204>3.0.co;2-9.
9
Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.预测干燥综合征相关非霍奇金淋巴瘤患者的预后。
PLoS One. 2015 Feb 27;10(2):e0116189. doi: 10.1371/journal.pone.0116189. eCollection 2015.
10
[Prognostic factors in Hodgkin and non-Hodgkin lymphomas].[霍奇金淋巴瘤和非霍奇金淋巴瘤的预后因素]
Bull Cancer. 2009 Apr;96(4):461-73. doi: 10.1684/bdc.2009.0844.

本文引用的文献

1
Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL).p80及内脏受累在儿童CD30间变性大细胞淋巴瘤(ALCL)中的预后意义
Med Pediatr Oncol. 2001 Aug;37(2):97-102. doi: 10.1002/mpo.1176.
2
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features.伯基特样淋巴瘤:西南肿瘤学组一项描述其表型、基因型和临床特征的研究
Blood. 2001 Jun 15;97(12):3713-20. doi: 10.1182/blood.v97.12.3713.
3
Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
短疗程B非霍奇金淋巴瘤型化疗是小儿间变性大细胞淋巴瘤的有效治疗方法:柏林-法兰克福-明斯特集团试验NHL-BFM 90报告
Blood. 2001 Jun 15;97(12):3699-706. doi: 10.1182/blood.v97.12.3699.
4
The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.法国儿科肿瘤学会LMB89方案:针对561例未经选择的B细胞淋巴瘤和L3白血病患儿的肿瘤负荷和初始反应量身定制的高效多药化疗。
Blood. 2001 Jun 1;97(11):3370-9. doi: 10.1182/blood.v97.11.3370.
5
Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology.间变性大细胞淋巴瘤:诊断血液病理学的变幻莫测
Mod Pathol. 2001 Mar;14(3):219-28. doi: 10.1038/modpathol.3880289.
6
Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.
Blood. 2000 Aug 15;96(4):1605-7.
7
[The many faces of anaplastic large cell lymphoma].[间变性大细胞淋巴瘤的多种表现]
Pathologe. 2000 Mar;21(2):124-36. doi: 10.1007/s002920050380.
8
Cell adhesion receptors in lymphoma dissemination.淋巴瘤播散中的细胞黏附受体
Blood. 2000 Mar 15;95(6):1900-10.
9
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.通过基因表达谱鉴定出的不同类型弥漫性大B细胞淋巴瘤。
Nature. 2000 Feb 3;403(6769):503-11. doi: 10.1038/35000501.
10
Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas.预后的临床病理因素,包括弥漫性大B细胞淋巴瘤中的免疫表达。
Pathol Int. 1999 Dec;49(12):1043-52. doi: 10.1046/j.1440-1827.1999.00980.x.